Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor

Anaplastic lymphoma kinase (ALK) rearrangement lung cancer responds to ALK tyrosine kinase inhibitors. It is known that many cases ultimately acquired resistance to crizotinib. However, a case of primary resistance is rare. We present a case of harboring exon 19 deletion in epidermal growth factor r...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wenxian, Jiang, Xiaowen, Song, Zhengbo, Zhang, Yiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712969/
https://www.ncbi.nlm.nih.gov/pubmed/26811689
http://dx.doi.org/10.2147/OTT.S97100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712969/
https://www.ncbi.nlm.nih.gov/pubmed/26811689
http://dx.doi.org/10.2147/OTT.S97100

Ejemplares similares